Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes
Veeral Ajmera(University of California San Diego), Rohit Loomba(University of California San Diego), Scarlett Lopez(University of California San Diego), Kaleb Tesfai(University of California San Diego), Ricki Bettencourt(University of California San Diego), Vanessa Cervantes(University of California San Diego), Pinelopi Manousou(Center for Digestive and Liver Diseases), Egbert Madamba(University of California San Diego), Lisa Richards(University of California San Diego), Erick Sandoval(University of California San Diego)
Cited by 30
Related Papers
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k